PRM-151 (recombinant human serum amyloid P/pentraxin 2) for the treatment of fibrosis.

Abstract

Serum amyloid P or pentraxin 2 (PTX2) is a highly phylogenetically conserved, naturally circulating plasma protein and a soluble pattern recognition receptor of the innate immune system. The unique binding activities of PTX2 suggest that it may localize specifically to sites of injury and function to aid in the removal of damaged tissue. The recent discovery of its ability to regulate certain monocyte differentiation states has identified PTX2 as a novel and potentially powerful antifibrotic agent. A fully recombinant form of the human PTX2 protein, designated PRM-151, has recently initiated human clinical trials. Here we review the molecular, cellular and structural biology of PRM-151/PTX2 in vitro and in several in vivo preclinical models of fibrotic disease that demonstrate its potential as a first-in-class natural modulator of fibrotic pathology with significant potential to treat a wide variety of human diseases.

• Authors: Jeremy S Duffield, Mark L Lupher Jr
• Journal: Drug news & perspectives (Drug News Perspect) Vol. 23 Issue 5 Pg. 305-15 (Jun 2010) ISSN: 0214-0934 [Print] United States
• PMID: 20603654 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
• Copyright: Copyright (c) 2010 Prous Science, S.A.U. or its licensors. All rights reserved.

Chemical References

• Homeodomain Proteins
• Nerve Tissue Proteins
• PRM-151
• Recombinant Proteins
• Serum Amyloid P-Component
• neuronal pentraxin
• C-Reactive Protein

Topics

• Amyloidosis (pathology)
• Animals
• C-Reactive Protein (therapeutic use)
• Cell Differentiation (drug effects)
• Cell Lineage (drug effects)
• Fibrosis (drug therapy, pathology)
• Homeodomain Proteins (therapeutic use)
• Humans
• Nerve Tissue Proteins (therapeutic use)
• Recombinant Proteins (therapeutic use)
• Serum Amyloid P-Component (therapeutic use)